Scarica l'app Stockscreener
21.66
5.66%
-1.30
Pre-mercato:
21.80
0.14
+0.65%
Precedente Chiudi:
$22.96
Aprire:
$22.98
Volume 24 ore:
1.03M
Relative Volume:
0.89
Capitalizzazione di mercato:
$2.45B
Reddito:
$6.94M
Utile/perdita netta:
$-212.39M
Rapporto P/E:
-8.9209
EPS:
-2.428
Flusso di cassa netto:
$-200.60M
1 W Prestazione:
+3.74%
1M Prestazione:
-8.92%
6M Prestazione:
+16.89%
1 anno Prestazione:
+156.03%
Intervallo 1D:
$21.58
$23.09
Intervallo di 1 settimana:
$19.45
$23.29
Portata 52W:
$7.96
$27.65
Immunome Inc Stock (IMNM) Company Profile
Nome
Immunome Inc
Settore
Industria
Telefono
610-321-3700
Indirizzo
18702 N. CREEK PARKWAY, BOTHELL
Compare IMNM vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
IMNM
Immunome Inc
|
21.66 | 2.60B | 6.94M | -212.39M | -200.60M | -2.428 |
VRTX
Vertex Pharmaceuticals Inc
|
434.52 | 110.03B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
638.88 | 67.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
806.46 | 50.76B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
297.45 | 40.12B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
151.56 | 32.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Immunome Inc Stock (IMNM) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-02-12 | Iniziato | H.C. Wainwright | Buy |
| 2025-12-01 | Iniziato | Truist | Buy |
| 2025-09-22 | Iniziato | Goldman | Buy |
| 2025-09-05 | Iniziato | Craig Hallum | Buy |
| 2025-04-02 | Iniziato | Lake Street | Buy |
| 2024-11-08 | Iniziato | Stephens | Overweight |
| 2024-05-31 | Iniziato | Piper Sandler | Overweight |
| 2024-04-30 | Iniziato | JP Morgan | Overweight |
| 2024-04-15 | Iniziato | Guggenheim | Buy |
| 2024-01-29 | Iniziato | Leerink Partners | Outperform |
| 2023-12-19 | Iniziato | Wedbush | Outperform |
| 2021-10-29 | Iniziato | Cantor Fitzgerald | Overweight |
Mostra tutto
Immunome Inc Borsa (IMNM) Ultime notizie
(IMNM) Movement as an Input in Quant Signal Sets - Stock Traders Daily
What Do Recent Insider Sales at Immunome (IMNM) Signal - Kavout
Immunome Inc stock (US45254C1062): biotech investor attention after oncology pipeline update - AD HOC NEWS
Immunome director Bienaime buys $103,500 in company stock By Investing.com - Investing.com Nigeria
Insider Buying: Jean Bienaime Acquires 5,000 Shares of Immunome Inc (IMNM) - GuruFocus
Immunome director Bienaime buys $103,500 in company stock - Investing.com
Director Bienaime adds 5,000 Immunome (IMNM) shares in open-market buy - Stock Titan
What Offers Immunome (IMNM) a Compelling Investment Opportunity? - Insider Monkey
Immunome (IMNM) moves 13.3% higher: Will this strength last? - MSN
Immunome Inc stock (US45254C1062): oncology deal momentum keeps biotech in focus - AD HOC NEWS
LifeSci Capital Maintains Immunome(IMNM.US) With Buy Rating, Maintains Target Price $40 - Moomoo
Immunome Inc stock (US45254C1062): oncology deal momentum keeps investors watching - AD HOC NEWS
Immunome (NASDAQ:IMNM) Stock Rating Upgraded by Wall Street Zen - MarketBeat
Immunome Is Maintained at Outperform by Leerink Partners - Moomoo
Point72 and Steven A. Cohen report 0% ownership in Immunome (IMNM) - Stock Titan
Redmile Group and Jeremy C. Green disclose 4.9% stake in Immunome (IMNM) - Stock Titan
IMNM Maintained by Leerink Partners -- Price Target Lowered to $33.00 - GuruFocus
T. Rowe Price (IMNM) files 13G/A showing 16.36M shares (14.5%) - Stock Titan
Research Analysts Offer Predictions for Immunome Q2 Earnings - MarketBeat
Sirenia Capital reports 6.1% stake in Immunome (NASDAQ: IMNM) via Schedule 13G - Stock Titan
Research Analysts Issue Forecasts for Immunome Q2 Earnings - MarketBeat
Immunome stock (US45254C1062): Institutional investors see $269M market cap drop - AD HOC NEWS
Goldman Sachs Maintains Immunome(IMNM.US) With Buy Rating, Maintains Target Price $35 - Moomoo
Liquidity Mapping Around (IMNM) Price Events - Stock Traders Daily
Piper Sandler Maintains Immunome(IMNM.US) With Buy Rating, Maintains Target Price $33 - Moomoo
IMNM Reiterated by HC Wainwright & Co. -- Price Target Maintained at $40 - GuruFocus
Analyst Reiterates Buy on Immunome, Maintains $40 Price Target on Varegacestat Progress and Pipeline Upside - TipRanks
Craig-Hallum Maintains Immunome(IMNM.US) With Buy Rating, Maintains Target Price $36 - Moomoo
Immunome Reports First Quarter 2026 Financial Results and Provides Business Update - BioSpace
Immunome 1Q Loss/Shr 48c >IMNM - Moomoo
IMNM SWOT Analysis: Key Insights from 10-Q Filing - GuruFocus
Immunome (IMNM) Advances Oncology Programs with Key Developments - GuruFocus
Immunome 1Q Loss $53.8M >IMNM - Moomoo
Immunome (NASDAQ: IMNM) files varegacestat NDA while Q1 loss grows on higher R&D - Stock Titan
Immunome Inc. 1Q 2026: Revenue $0 EPS $(0.48) — 10-Q Summary - TradingView
Immunome Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Immunome, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Cancer NDA and wider Q1 2026 loss at Immunome (IMNM) with strong Phase 3 data - Stock Titan
Immunome Inc stock (US45254C1062): NDA submission for varegacestat in desmoid tumors - AD HOC NEWS
TradingKey - TradingKey
Immunome, Inc. (IMNM) Reports Submission of an NDA for Varegacestat in Desmoid Tumors - Insider Monkey
Assessing Immunome (IMNM) Valuation After Varegacestat NDA And Phase 3 Desmoid Tumor Success - Yahoo Finance
10 Best Biotech Stocks to Invest In According to Billionaire Steve Cohen - Insider Monkey
Nan Fung Trinity HK Ltd. Grows Position in Immunome, Inc. $IMNM - MarketBeat
Assessing Immunome (IMNM) Valuation As Premium P/B And DCF Signals Point In Different Directions - Sahm
Immunome earnings up next: Cash burn eyed after NDA filing By Investing.com - Investing.com Australia
Immunome earnings up next: Cash burn eyed after NDA filing - Investing.com UK
Immunome Inc Azioni (IMNM) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Immunome Inc Azioni (IMNM) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Higgins Jack | Chief Scientific Officer |
Apr 02 '26 |
Sale |
21.64 |
9,438 |
204,238 |
22,000 |
| Rosett Max | Chief Financial Officer |
Apr 02 '26 |
Option Exercise |
1.22 |
71,561 |
87,053 |
119,037 |
| Rosett Max | Chief Financial Officer |
Apr 02 '26 |
Sale |
21.92 |
65,000 |
1,424,916 |
54,037 |
2.98%
1.33%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):